Details

Autor(en) / Beteiligte

• Rifkin, Robert M
• Costello, Caitlin L
• Birhiray, Ruemu E
• Kambhampati, Suman
• Richter, Joshua
• Abonour, Rafat
• Lee, Hans C
• Stokes, Michael
• Ren, Kaili
• Stull, Dawn Marie
• Cherepanov, Dasha
• Bogard, Kimberly
• Noga, Stephen J
• Girnius, Saulius

Titel

class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma

Ist Teil von

• Future oncology (London, England), 2024-01, Vol.20 (3), p.131-143

Ort / Verlag

England: Future Medicine Ltd

Erscheinungsjahr

2024

Beschreibungen/Notizen

• To compare the effectiveness of -class transition to all-oral ixazomib-lenalidomide-dexamethasone (IRd) following parenteral bortezomib (V)-based induction versus continued V-based therapy in US oncology clinics. Non-transplant eligible patients with newly diagnosed multiple myeloma (MM) receiving transition to IRd (N = 100; US MM-6), or V-based therapy (N = 111; INSIGHT MM). Following inverse probability of treatment weighting, overall response rate was 73.2% with IRd versus 57.5% with V-based therapy (p < 0.0001). Median duration of treatment was 10.8 versus 5.3 months (p < 0.0001). Overall, 18/24% of patients discontinued IRd/V-based therapy due to adverse events. IRd after V-based induction was associated with significantly improved overall response rate and duration of treatment than continued V-based combination therapy. : US MM-6: ; INSIGHT MM: ( )